Clinical efficacy of piracetam in treatment of breath-holding spells

Pediatric Neurology

Volumn 18, Issue 1, 1998, Pages 41-45

  Donma, Metin M ^a,b  

^a MINISTRY OF HEALTH   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PIRACETAM; PLACEBO;

ANAMNESIS; ARTICLE; BREATH HOLDING; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; TREATMENT OUTCOME;

CHILD BEHAVIOR DISORDERS; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; PIRACETAM; RESPIRATION; SYNCOPE; TREATMENT OUTCOME;

EID: 0031917297     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(97)00153-7     Document Type: Article

References (51)

1. [1] Apak S. Childhood epilepsy, Istanbul: Sanal Publishing Inc., 1986:110-1.
2. [2] Lockman LA. Breath-holding spells. In: Swaiman KF, ed. Pediatric neurology. St. Louis: CV Mosby; 1989:443-6.
3. [3] Ökten A. Breath-holding spells. Katki Paediatr J 1986;7(1):57-9.
4. [4] Scher MS. Pediatric EEG and evoked potentials, In: Swaiman KF, ed. Pediatric neurology, St. Louis: CV Mosby; 1989:67-103.
5. [5] Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Rev 1994;19:180-222.
6. [6] Strubbe JN, Cyprysiak E. Dérivés de l'î.cide (2-oxopyrrolidone) acétique. Rev Industrie Chimique Belge 1967;32:112-4.
7. [7] Kulinski UI, Klimova AD. The radioprotective effect of GABA-tropic substances, gamma-hydroxybutyrate and piracetam. Radiobiologiia 1993;33:133-6.
8. [8] Samvelian VM, Malakian MG, Badzhinian SA. Antiarrhythmic action of piracetam. Pharmacol Toxicol 1990;53:22-3.
9. [9] Sirotina IV, Aleksandrova ZD, Bogatyreva NV, et al. The results of the therapeutic monitoring of piracetam in parturients and newborn infants. Exp Clin Pharmacol 1992;55:53-6.
10. [10] Simeon J, Waters B, Resnick M. Clinical and EEG effects of piracetam with learning disorders. Proceedings of the First International Symposium on Nootropic Drugs; 1979 Oct 25-26; Rio de Janeiro. Rio de Janeiro: VCB, 1979:81-8.
11. [11] Strehl W, Brosswitz A. Klinische Beobachtungen über die Wirkung von UCB 6215 auf einige Hirnfunktionen bei Schulkindern im doppelten Blindversuch. Therapiewoche 1972;22:2975-9.
12. [12] Duran CH, Solomonovici AM. Intérét de l'utilisation du piracetam (UCB 6215) dans les trouble de l'adaptation de l'enfant. Méd Infant 1971;78:478-84.
13. [13] Thiebauld C. Amélioration des performances intellectuelles. Contribution d'une thérapeutique corticale spécifique. Actes de 1' 38ème Congrès Français de Médicin, 1971 Sept 12-16; Beyrouth.
14. [14] Dubois B, Fontaine G. Expérimentation clinique du piracetam. Lille Méd 1973;18(suppl 3):832-5.
15. [15] Vialatte J. Expérimentation clinique chez l'enfant (du piracetam). Vie Méd Can Fr 1973;18:2327-30.
16. [16] Flegel G. Die Wirkung von Piracetam auf die Hirnfunktion bei Jugendlichen. Fortschr Med 1975;93:1183-6.
17. [17] Umdenstock R, Guibert J. Essai du piracetam (Nootropyl). Gaz Méd Limousine 1974;6:43-6.
18. [18] Ernst J. Les indications du piracetam en pédo-psychiatrie. J des Sci Méd de Lille 1973;91:39-42.
19. [19] Lafon R. Essai du piracetam en neuropsychiatrie infantile. Ann Méd Psychol 1972;2:425-31.
20. [20] Khosroshahi HE, Bozkurt V, Sadikoǧlu N, et al. Treatment of nocturnal enuresis: A placebo-controlled trial with piracetam, diphenyl hydantoin and psychotherapy. Turk J Pediatr 1989;31:215-20.
21. [21] Pogady J. Pyrrolidone acetamide in the treatment of enuresis nocturna in pedopsychiatry. Acta Ther 1977;3:217-28.
22. [22] Wocjan J, Chmiel B, Eible M. The therapeutic value of Nootropil (piracetam UCB) in pediatric neuro-surgery. Proceedings of the International Congress on Child Neurology. 1975 Oct. 6-10; Toronto.
23. [23] Fialho J. Dromia y piracetam: Una asociacion util en el tratamiento del s.de Down. Etude Comparative. Tempo Medico 1977; 30: 944.
24. [24] Maritz NG, Muller FO, Pompe HF, Piracetam in the management of spasticity in cerebral palsy. S Afr Med Tydskrif 1978;53:889-91.
25. [25] Trevisio A, Rigardetto R. Piracetam nel trattamento dei disturbi del linguaggio in etä evolutive. Minerva Pediatr 1977;29:1267-72.
26. [26] Silbert PL, Gubbay SS. Familial cyanotic breath-holding spells. J Paediatr Child Health 1992;28:254-6.
27. [27] Poets CF, Samuels MP, Wardrop CA, et al. Reduced haemoglobin levels in infants presenting with apparent life-threatening events: A retrospective investigation. Acta Paediatr 1992;81:319-21.
28. [28] Colina KF, Abelson HT. Resolution of breath-holding spells with treatment of concomitant anemia. J Pediatr 1995;126:395-7.
29. [29] Pitkänen A. Treatment with antiepileptic drugs. Neurology 1996;47(suppl 1):12-6.
30. [30] Pellock JM. Antiepileptic drug therapy in the United States. Neurology 1995;45(suppl 2):17-24.
31. [31] Lammers MW, Hekster YA, Keyser A, et al. Use of antiepileptic drugs in a community-dwelling population. Neurology 1996;46: 62-7.
32. [32] Barbagallo A, Latona R, Martines R. Sull'azione terapeutica del piracetam (Nootropil) nelle mepilessie. Igiene Mentale, fasc. III, 1978; July-Sept. 1-56.
33. [33] Barbagallo A, Latona R, Martines R. Attivitá terapeutica del piracetam (Nootropil) nel ritardo psico-motoric degli epilettici. Igiene Mentale, fasc. III, 1978; July-Sept. 1-44.
34. [34] Barbagallo A, Latona R, Martines R. Sull'azione terapeutica del piracetam (Nootropil) nel disturbi comportamentali degli epilettici. Igiene Mentale, fasc. III, 1978; July-Sept. 1-29.
35. [35] Kunneke PS, Malan GM. A controlled clinical trial on the effect of piracetam in epileptic children. Br J Clin Pract 1979;33:266-71.
36. [36] Vernon MW, Sorkin EM. Piracetam: An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1991;1:17-35.
37. [37] Mondadori C, Häusler A. Aldosterone receptors are involved in the mediation of the memory-enhancing effects of piracetam. Brain Res 1990;524:203-7.
38. [38] Geber J, Cop J, Cvitanovic B, et al. The effect of piracetam on the recurrent inhibition of motor neurons. Neurologija 1990;39:163-8.
39. [39] Gallai V, Mazzotta G. GelGatto F, et al. A clinical and neurophysiological trial on nootropic drugs in patients with mental decline. Acta Neurol 1991;13:1-12.
40. [40] Gini EK, Sonnet J. Use of piracetam improves sickle cell deformability in vitro and in vivo. J Clin Pathol 1987;40:99-102.
41. [41] DiMario FJ Jr, Burleson JA. Autonomic nervous system function in severe breath-holding spells. Pediatr Neurol 1993;9:268-74.
42. [42] DiMario FJ Jr. Breath-holding spells in childhood (Review). Am J Dis Child 1992;146:125-31.
43. [43] DiMario FJ Jr, Chee CM, Berman PH. Pallid breath-holding spells. Evaluation of the autonomic nervous system. Clin Pediatr 1990;29:17-24.
44. [44] Danilov VI, Gorozhanin AV, Studentsova IA. The effect of dimephosphon, sermion and piracetam on the reactivity of the cerebral vessels, on local cerebral blood flow and on oxygen tension in brain tissue. Eksp Klin Farmakol 1994;57:19-22.
45. [45] Sirotina IV, Aleksandrova ZD, Bogatyreva NV, et al. The results of the therapeutic monitoring of piracetam in parturients and newborn infants. Eksp Klin Farmakol 1992;55:53-6.
46. [46] Greenamyre JT, Porter RHP. Anatomy and physiology of glutamate in the CNS. Neurology 1994;44(suppl 8):S7-S13.
47. [47] Meldrum BS. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994;44(suppl 8):S14-S23.
48. [48] Lipton SA. Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-22.
49. [49] Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
50. [50] Sunderland PM. Structure and function of the nervous system. In: McCance KL, Muether SE, eds. Pathophysiology: The biologic basis for disease in adults and children. St. Louis: Mosby-Year Book, 1994: 397-436.
51. [51] Chiarenze GA, Ragaini C, Guareschi Cazzullo A. The acute and chronic administrations of piracetam affect the movement-related brain macropotentials. Int J Psychophysiol 1990;8:223-34.